Cargando…

Evidence for treating rheumatoid arthritis to target: results of a systematic literature search

OBJECTIVES: To summarise existing evidence on a target oriented approach for rheumatoid arthritis (RA) treatment. METHODS: We conducted a systematic literature search including all clinical trials testing clinical, functional, or structural values of a targeted treatment approach. Our search covered...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schoels, Monika, Knevel, Rachel, Aletaha, Daniel, Bijlsma, Johannes W J, Breedveld, Ferdinand C, Boumpas, Dimitrios T, Burmester, Gerd, Combe, Bernard, Cutolo, Maurizio, Dougados, Maxime, Emery, Paul, van der Heijde, Desirée, Huizinga, Tom W J, Kalden, Joachim, Keystone, Edward C, Kvien, Tore K, Martin-Mola, Emilio, Montecucco, Carlomaurizio, de Wit, Maarten, Smolen, Josef S
Formato:	Texto
Lenguaje:	English
Publicado:	BMJ Group 2010
Materias:	Clinical and Epidemiological Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3015093/ https://www.ncbi.nlm.nih.gov/pubmed/20237123 http://dx.doi.org/10.1136/ard.2009.123976

Ejemplares similares

Treating rheumatoid arthritis to target: recommendations of an international task force
por: Smolen, Josef S, et al.
Publicado: (2010)

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
por: Smolen, Josef S, et al.
Publicado: (2010)

Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement
por: Schoels, Monika M, et al.
Publicado: (2013)

Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update
por: Stoffer, Michaela A, et al.
Publicado: (2016)

Treating Rheumatoid Arthritis to Target: multinational recommendations assessment questionnaire
por: Haraoui, Boulos, et al.
Publicado: (2011)

Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions
por: Smolen, Josef S, et al.
Publicado: (2013)

Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial
por: Stamm, Tanja Alexandra, et al.
Publicado: (2018)

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update
por: Smolen, Josef S, et al.
Publicado: (2014)

Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis
por: Buch, Maya H, et al.
Publicado: (2011)

2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations
por: van der Heijde, Désirée, et al.
Publicado: (2015)

Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force
por: Smolen, Josef S, et al.
Publicado: (2016)

Defining cut-off values for disease activity states and improvement scores for patient-reported outcomes: the example of the Rheumatoid Arthritis Impact of Disease (RAID)
por: Dougados, Maxime, et al.
Publicado: (2012)

Introducing RMD Open
por: Cutolo, Maurizio, et al.
Publicado: (2015)

Achieving comprehensive disease control in patients with early and established rheumatoid arthritis treated with adalimumab plus methotrexate versus methotrexate alone
por: Keystone, Edward C, et al.
Publicado: (2017)

Evaluation of newly proposed remission cut-points for disease activity score in 28 joints (DAS28) in rheumatoid arthritis patients upon IL-6 pathway inhibition
por: Schoels, M., et al.
Publicado: (2017)

Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis
por: Kerschbaumer, Andreas, et al.
Publicado: (2020)

Treating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: results of a systematic literature search to support an international treat-to-target recommendation in spondyloarthritis
por: Schoels, M M, et al.
Publicado: (2014)

Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population
por: Weinblatt, Michael E., et al.
Publicado: (2015)

Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology
por: Buch, Maya H, et al.
Publicado: (2015)

Certolizumab Pegol Efficacy Across Methotrexate Regimens: A Pre‐Specified Analysis of Two Phase III Trials
por: Combe, Bernard, et al.
Publicado: (2016)

Remission by composite scores in rheumatoid arthritis: are ankles and feet important?
por: Kapral, Theresa, et al.
Publicado: (2007)

Erratum to: Rheumatology training experience across Europe: analysis of core competences
por: Sivera, Francisca, et al.
Publicado: (2016)

Rheumatology training experience across Europe: analysis of core competences
por: Sivera, Francisca, et al.
Publicado: (2016)

Changes in patient characteristics in anti-tumour necrosis factor clinical trials for rheumatoid arthritis: results of an analysis of the literature over the past 16 years
por: Rahman, Mahboob U, et al.
Publicado: (2011)

Understanding emerging treatment paradigms in rheumatoid arthritis
por: Breedveld, Ferdinand C, et al.
Publicado: (2011)

Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force
por: Smolen, Josef S, et al.
Publicado: (2014)

A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immune-mediated inflammatory diseases
por: Kastrati, Kastriot, et al.
Publicado: (2022)

Interpreting big-data analysis of retrospective observational data
por: Huizinga, Tom W J, et al.
Publicado: (2020)

When rheumatologists report that they agree with a guideline, does this mean that they practise the guideline in clinical practice? Results of the International Recommendation Implementation Study (IRIS)
por: Gvozdenović, Emilia, et al.
Publicado: (2016)

The appropriate use of non-steroidal anti-inflammatory drugs in rheumatic disease: opinions of a multidisciplinary European expert panel
por: Burmester, Gerd, et al.
Publicado: (2010)

Unmet need in rheumatology: reports from the Targeted Therapies meeting 2019
por: Winthrop, Kevin L, et al.
Publicado: (2020)

Long-term efficacy and safety of biologics in rheumatoid arthritis
por: Montecucco, Carlomaurizio
Publicado: (2012)

An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status
por: van der Bijl, Arie E., et al.
Publicado: (2008)

EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update
por: Gossec, Laure, et al.
Publicado: (2020)

Cardiovascular Comorbidities Relate More than Others with Disease Activity in Rheumatoid Arthritis
por: Crepaldi, Gloria, et al.
Publicado: (2016)

Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension
por: Keystone, Edward, et al.
Publicado: (2014)

The changing landscape of biosimilars in rheumatology
por: Dörner, Thomas, et al.
Publicado: (2016)

Cardiovascular and selected comorbidities in early arthritis and early spondyloarthritis, a comparative study: results from the ESPOIR and DESIR cohorts
por: Gherghe, Ana Maria, et al.
Publicado: (2015)

Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative
por: Visser, K, et al.
Publicado: (2008)

The likelihood of persistent arthritis increases with the level of anti-citrullinated peptide antibody and immunoglobulin M rheumatoid factor: a longitudinal study of 376 patients with very early undifferentiated arthritis
por: Mjaavatten, Maria D, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_ctij8pvlg6d92bsn6dp491m5lb